UK Parliament Invests £1.6 Billion Annually in Cancer Research

Strategic Insights -

The UK Parliament emphasizes the significance of research in tackling cancer, investing £1.6 billion per year through the National Institute for Health and Care Research (NIHR). Cancer research is a top priority, with £133 million allocated in 2023-2024. The TRANSFORM trial is a notable example of this investment, aiming to find the best prostate cancer screening method. Prostate Cancer UK (PCUK) leads the trial, with the Government contributing £16 million. The Frimley Park Integrated Care System is also involved in supporting the delivery of research, including prostate cancer studies.

Key Takeaways:

  • The UK Parliament invests £1.6 billion annually in cancer research through the National Institute for Health and Care Research (NIHR).
  • Cancer research is a high-priority area, with £133 million allocated in 2023-2024.
  • The TRANSFORM trial is a £42 million initiative to find the best way to screen men for prostate cancer.
  • Prostate Cancer UK (PCUK) leads the development of the trial, with the Government contributing £16 million.
  • The Frimley Park Integrated Care System is part of the NIHR Research Delivery Network and supports delivery of research, including prostate cancer studies.
  • The NIHR welcomes funding applications for research into human health and care, including prostate cancer.
  • £42 million is allocated for the TRANSFORM trial to screen men for prostate cancer effectively.
  • £16 million is contributed by the Government through the Department for the TRANSFORM trial.
  • The TRANSFORM trial focuses on finding the best prostate cancer screening method before the disease becomes advanced and harder to treat.

Statistics:

  • £1.6 billion is invested annually in cancer research through the NIHR.
  • £133 million was allocated for cancer research in 2023-2024.
  • £42 million is set aside for the TRANSFORM trial.
  • £16 million is contributed by the Government through the Department for the TRANSFORM trial.
  • The Government contributed £16 million towards the trial, with PCUK leading the development.

Sources:

  • UK Parliament Written Answer by Ashley Dalton, 4 August 2025
  • Prostate Cancer UK (PCUK)